Protara Therapeutics (TARA) Current Assets (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Current Assets of $140.0 million for Q1 2026, up 10.64% year-over-year from $126.5 million in Q1 2025, and down 12.23% quarter-over-quarter from $159.5 million in Q4 2025.
Protara Therapeutics (TARA) Current Assets (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Current Assets for 14 consecutive years, with $140.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 10.64% year-over-year to $140.0 million; the TTM figure through Mar 2026 stood at $140.0 million (up 10.64% YoY), while the FY2025 annual figure was $159.5 million, down 7.35% from the prior year.
- Current Assets declined to $140.0 million in Q1 2026 per TARA's latest filing, from $159.5 million in the prior quarter.
- Across five years, Current Assets topped out at $172.2 million in Q4 2024 and bottomed at $57.9 million in Q1 2024.
- Historically, Current Assets has averaged $105.7 million across 5 years, with a median of $94.6 million in 2023.
- On a YoY basis, Current Assets climbed as much as 150.57% in 2024 and fell as far as 38.79% in 2024.
- Protara Therapeutics' Current Assets stood at $86.1 million in 2022, then dropped by 20.25% to $68.7 million in 2023, then jumped by 150.57% to $172.2 million in 2024, then retreated by 7.35% to $159.5 million in 2025, then dropped by 12.23% to $140.0 million in 2026.
- Business Quant data shows TARA's Current Assets at $140.0 million in Q1 2026, $159.5 million in Q4 2025, and $135.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - | 146.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 146.15 Mn |
| Mar 31, 2026 | 140.00 Mn |
| Dec 31, 2025 | 159.50 Mn |
| Sep 30, 2025 | 135.64 Mn |
| Jun 30, 2025 | 125.09 Mn |
| Mar 31, 2025 | 126.53 Mn |
| Dec 31, 2024 | 172.16 Mn |
| Sep 30, 2024 | 85.08 Mn |
| Jun 30, 2024 | 92.21 Mn |
| Mar 31, 2024 | 57.91 Mn |
| Dec 31, 2023 | 68.71 Mn |
| Sep 30, 2023 | 77.81 Mn |
| Jun 30, 2023 | 84.27 Mn |
| Mar 31, 2023 | 94.62 Mn |
| Dec 31, 2022 | 86.15 Mn |
| Sep 30, 2022 | 98.67 Mn |
| Jun 30, 2022 | 101.09 Mn |
| Mar 31, 2022 | 90.69 Mn |
| Dec 31, 2021 | 93.11 Mn |
| Sep 30, 2021 | 95.70 Mn |